Lisata Therapeutics, Inc.
$2.83
▲
0.2%
2026-04-21 07:58:01
www.lisata.com
NCM: LSTA
Explore Lisata Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$25.56 M
Current Price
$2.83
52W High / Low
$5.07 / $1.81
Stock P/E
—
Book Value
$1.68
Dividend Yield
—
ROCE
-124.1%
ROE
-75.53%
Face Value
—
EPS
$-1.91
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
21
Beta
1.11
Debt / Equity
0
Current Ratio
5.76
Quick Ratio
5.76
Forward P/E
-7.59
Price / Sales
266.19
Enterprise Value
$29.04 M
EV / EBITDA
-1.61
EV / Revenue
170.83
Rating
None
Target Price
$9.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Summit Therapeutics Inc. | $24.32 | — | $18.91 B | — | -161.37% | -2.06% | $36.91 / $13.83 | $0.85 |
| 2. | Evommune, Inc. | $27.97 | — | $988.7 M | — | -39.16% | -54.42% | $33.2 / $13.88 | $6.52 |
| 3. | Nurix Therapeutics, Inc. | $17.04 | — | $1.81 B | — | -47.48% | -61.4% | $22.5 / $8.2 | $4.65 |
| 4. | Boundless Bio, Inc. | $1.6 | — | $35.4 M | — | -43.97% | -46.69% | $1.78 / $0.96 | $4.4 |
| 5. | Revelation Biosciences, Inc. | $1.16 | — | $4.32 M | — | -94.64% | -1.31% | $43.48 / $0.99 | $5.59 |
| 6. | Senti Biosciences, Inc. | $1.14 | — | $34.26 M | — | -171.08% | -2.18% | $5.1 / $0.77 | $0.18 |
| 7. | Immatics N.V. | $11.25 | — | $1.51 B | — | -35.05% | -37.1% | $12.41 / $3.94 | $4.18 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.1 M | 0 M | 0.07 M | 0 M | 1 M | — |
| Operating Profit | -3.08 M | -4.41 M | -4.87 M | -5.85 M | -4.95 M | — |
| Net Profit | -2.95 M | -4.25 M | -4.66 M | -4.72 M | -4.61 M | — |
| EPS in Rs | -0.33 | -0.47 | -0.52 | -0.52 | -0.51 | -0.59 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.17 M | 1 M | 0 M | 0 M |
| Operating Profit | -18.21 M | -22.41 M | -25.71 M | -57.6 M |
| Net Profit | -16.59 M | -19.98 M | -20.84 M | -54.23 M |
| EPS in Rs | -1.84 | -2.21 | -2.31 | -6 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 17.74 M | 35 M | 54.69 M | 73.03 M |
| Total Liabilities | 3.14 M | 5.68 M | 6.8 M | 6.71 M |
| Equity | 14.86 M | 29.57 M | 48.15 M | 66.58 M |
| Current Assets | 17.7 M | 34.58 M | 53.92 M | 71.88 M |
| Current Liabilities | 3.07 M | 5.61 M | 6.59 M | 6.38 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -15.95 M | -19.36 M | -20.03 M | -21.17 M |
| Investing CF | 15.09 M | 13.23 M | 10.1 M | 28.91 M |
| Financing CF | 0.6 M | -0.21 M | 0.39 M | -0.22 M |
| Free CF | -15.98 M | -19.36 M | -20.03 M | -21.45 M |
| Capex | -0.03 M | — | — | -0.28 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -83% | — | — | — |
| Earnings Growth % | 17.01% | 4.1% | 61.57% | — |
| Profit Margin % | -9756.47% | -1998.5% | — | — |
| Operating Margin % | -10711.18% | -2240.9% | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -10625.29% | -2223.5% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2022-09-15 | 1:0.0666667 |